Publication
Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase II study (GeNeS1S trial).
Yoshiaki Nagatani, Naoko Chayahara, Hironaga Satake, Hisateru Yasui, Takeshi Sugimoto, Hirochika Toyama, Kazutoshi Tobimatsu, Eriko Ito, Yutaro Usui, Taiji Koyama, Shiro Kimbara, Yoshinori Imamura, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Hironobu Minami
- Source
- PubMed
- Retrieved
- Oct 2, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261002-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: S-1 has demonstrated non-inferiority to gemcitabine (GEM) in overall survival (OS) in advanced pancreatic cancer and superiority in the adjuvant setting for resectable disease. This study evaluated the efficacy and safety of S-1 combined with GEM plus nab-paclitaxel (nPTX) in advanced…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Pancreatic Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available